

Governing Body Meeting			
Date:	Tuesday 9 November 2021	Time:	2:30 pm
Venue:	MS Teams		
Questions from the general public received in advance			

Email received 13/09/2021

A range of Planning Guidance's have been published last week by NHS England, the PCN Planning Guidance Annex B stated "the IIF (Investment Impact Fund) will reward increased prescribing of DPIs and SMIs where clinically appropriate" going on to say, "by 2023/24 only 25% of non-salbutamol inhalers prescribed will be MDIs". I am interested to understand the views of the Pan Mersey CCGs & Cheshire & Mersey ICS on how such a multiyear direct incentivisation of Primary Care prescribing from NHS England appears to offer an increase low CO2 inhaler prescribing but presents a paradox that the increases in incentivised inhaler prescription may increase pressure on the Pan Mersey CCGs and Cheshire & Mersey ICS drugs budget and its ability to take advantage of significant in-year prescribing savings that some current inhaler devices can offer now ?

Liverpool CCG Response:

Thank you for your query. Liverpool Clinical Commissioning Group (CCG) is aware that a movement towards DPI is likely to increase cost and is taking the long-term view that as DPI becomes more commonplace prices will stabilise and reduce as production increases.

The CCG does have representation on the Cheshire and Merseyside Green Inhaler Prescribing Group and has been involved in discussions around this. It is believed that there is currently a level of over prescribing and work is underway to promote the review of patients prescribed high volumes of salbutamol annually in order to ascertain that they are managed appropriately. The Cheshire and Merseyside group will also be promoting tools and resources to support prescribers and pharmacies to check patients' techniques to ensure they are getting the benefit of their inhalers.